Steinberg D
Med Clin North Am. 1975 Mar;59(2):363-73. doi: 10.1016/s0025-7125(16)32038-7.
Although definite improvement in the treatment of acute myelogenous leukemia has taken place, the outlook for patients remains grim. The current aggressive approach to treatment, entailing a program of chemotherapy which almost invariably produces bone marrow aplasia and considerable toxicity, has been the subject of some controversy. Selected aspects of management are discussed.